帕金森病与炎症反应关系研究进展

[1] The inflammatory response in the Parkinson brain. Hunot S,Hartmann A,Hirsch EC. Clinical Neuroscience Research . 2001

[2] Changes in cytokines and neurotrophins in Parkinson’s disease. Nagatsu T,Mogi M,Ichinose H,et al. Journal of Neural Transmission . 2000

[3] Fcepsilon RII/CD23 is expressed in Parkinson’s disease and induces, in vitro,producing of nitric oxide and tumor necrosis factor-alpha in glia cells. Hunot S,Dugas N,Faucheux B,et al. The Journal of Neuroscience . 1999

[4] Blood vessels change in the mesencephalon of patients with Parkinson’s disease. Faucheux B,Bonnet AM,Agid Y,et al. The Lancet . 1999

[5] The inflammatory reaction following 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine intoxication in mouse. Kurkowska JI,Wronska A,Kohutnicka M,et al. Experimental Neurology . 1999

[6] Inducible nitric oxide sythase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Liberatore G,Jackson-Lewis V,Vukosavic S,et al. Nature Medicine . 1999

[7] Blockade of microglia activation is neuroprotective in the MPTP mouse model of Parkinson disease. Wu DC,Jackson V,Vila M,et al. The Journal of Neuroscience . 2002

[8] Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration. Teismann P,Tieu K,Choi DK,et al. Proceedings of the National Academy of Sciences of the United States of America . 2003

[9] Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. He Y,Appel S,Le W. Brain Research . 2001

[10] Increase in level of tumor necrosis factor in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-αinduction. Mogi M,Togari A,Tanaka K,et al. Neuroscience Letters . 1999

[1] The inflammatory response in the Parkinson brain. Hunot S,Hartmann A,Hirsch EC. Clinical Neuroscience Research . 2001

[2] Changes in cytokines and neurotrophins in Parkinson’s disease. Nagatsu T,Mogi M,Ichinose H,et al. Journal of Neural Transmission . 2000

[3] Fcepsilon RII/CD23 is expressed in Parkinson’s disease and induces, in vitro,producing of nitric oxide and tumor necrosis factor-alpha in glia cells. Hunot S,Dugas N,Faucheux B,et al. The Journal of Neuroscience . 1999

[4] Blood vessels change in the mesencephalon of patients with Parkinson’s disease. Faucheux B,Bonnet AM,Agid Y,et al. The Lancet . 1999

[5] The inflammatory reaction following 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine intoxication in mouse. Kurkowska JI,Wronska A,Kohutnicka M,et al. Experimental Neurology . 1999

[6] Inducible nitric oxide sythase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Liberatore G,Jackson-Lewis V,Vukosavic S,et al. Nature Medicine . 1999

[7] Blockade of microglia activation is neuroprotective in the MPTP mouse model of Parkinson disease. Wu DC,Jackson V,Vila M,et al. The Journal of Neuroscience . 2002

[8] Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration. Teismann P,Tieu K,Choi DK,et al. Proceedings of the National Academy of Sciences of the United States of America . 2003

[9] Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. He Y,Appel S,Le W. Brain Research . 2001

[10] Increase in level of tumor necrosis factor in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-αinduction. Mogi M,Togari A,Tanaka K,et al. Neuroscience Letters . 1999